Compare PLBL & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLBL | ARQT |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | Indonesia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.3B |
| IPO Year | N/A | 2020 |
| Metric | PLBL | ARQT |
|---|---|---|
| Price | $8.80 | $23.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 3.1K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | N/A | $34.46 |
| Revenue Next Year | N/A | $29.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $5.60 | $11.86 |
| 52 Week High | $13.48 | $31.77 |
| Indicator | PLBL | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 50.47 |
| Support Level | $7.38 | $22.56 |
| Resistance Level | $9.68 | $27.26 |
| Average True Range (ATR) | 0.59 | 0.95 |
| MACD | 0.07 | 0.28 |
| Stochastic Oscillator | 56.07 | 74.71 |
Polibeli Group Ltd is engaged in goods trading and others to promote the circulation of goods with a focus on making trading easier. The products offered by the company include consumer electronic accessories, household appliances, skincare products, oral-care products, cosmetics products, toys and game products, and health-care products. Geographically, the company derives the majority of its revenue from Japan.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.